Abstract:Introduction: Diffusion weighted magnetic resonance spectroscopy (DW-MRS) is useful for evaluation of the intracellular environment [1]. Previous studies showed that the most abundant metabolites that are detected by H-MRS are primarily located in the intracellular compartment of the brain and therefore DW-MRS offers excellent tools to specifically measure the intracellular response to cerebral injury [2]. The pathological changes in cells of glioma and metastatic tumor, the most common types of tumor in human brain, are related to the diagnosis and treatment of cerebral tumors. In this study, the apparent diffusion coefficients of brain metabolites were measured by DW-MRS on a clinical MR scanner for detecting pathological changes in cases of glioma and metastatic tumor in human brain. Methods: Ten glioma patients (6 males and 4 females, mean age 46±15.9 years, range 11-62 years) and six metastatic tumor patients (2 males and 4 females, mean age 70±7.6 years, range 65-84 years) were recruited for this study. Twelve age and sexual-matched health controls (4 males and 8 females, mean age 67±8.4 years, range 60-78 years) were selected for metastatic tumor patients. All the controls were free from neurological or psychiatric disease and their brain MRI scans were normal. All subjects had given their permission to be part of the study which was proved by the Investigational Review Board at our hospital. The DW-MRS sequence based on point resolved spectroscopy (PRESS) sequence technique was implemented for this study. The equipment used for the MR examinations was a 3.0T clinical wholebody system (Signa EXCITE HD; General Electric, Milwaukee, WI) with gradients with a maximum amplitude 40 mT/m and a maximum slew rate 150 mT/m/ms. Parameters for the DW-MRS sequence were as follows: TR 2000 ms, TE 144 ms, voxel size 2×2×2 cm (8 mL), spectral width 5000 HZ, and data points 4096. Data were acquired at only two different b-factor values: 45 and 1050 s/mm. The region of interests of DW-MRS were located in 1) the lesion area of glioma patients and its opposite un-affected areas; 2) the lesion area of metastatic tumor patients and 3) the left frontal cortex of health controls (Fig. 1). Post-spectral processing was carried out by SAGE software (GE Medical Systems). Pure water subtraction was used to reduce residual water from each suppressed frame. Phase corrections were performed before the summation of FIDs. Since the integral peak area was more sensitive to the random noise [4], peak height was used to determine the signal intensity of metabolites in this study. The apparent diffusion coefficients (ADCs) value was estimated by the following equation: ( ) ( ) ( ) 2 1 2 1 ADC=-ln S b S b b -b ⎡ ⎤ ⎣ ⎦ Where S (b1), and S (b2) are the signal intensities for the two b-values, b1 and b2.

Metabolic profiles of human brain parenchyma and glioma for rapid tissue diagnosis by targeted desorption electrospray ionization mass spectrometry

Using Arterial–venous Analysis to Characterize Cancer Metabolic Consumption in Patients

Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry

Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry

Tmet-23. Mass Spectrometry-Based Metabolic Profiling And Imaging Of Astrocyte And Glioblastoma Invasive Margin Cells

Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer

Tumor-Promoted Changes in Pediatric Brain Histology Can Be Distinguished from Normal Parenchyma by Desorption Electrospray Ionization Mass Spectrometry Imaging

Rapid Determination of Isocitrate Dehydrogenase Mutation Status of Human Gliomas by Extraction Nanoelectrospray Using a Miniature Mass Spectrometer

Mass Spectrometric Analysis of Cerebrospinal Fluid Protein for Glioma and Its Clinical Application

Noninvasive Delineation of Glioma Infiltration with Combined 7T Chemical Exchange Saturation Transfer Imaging and MR Spectroscopy: A Diagnostic Accuracy Study

In Vitro Brain Tumors: Initial Study Using High Resolution Magic Angle Spinning 1H MR Spectroscopy

Integrating HRMAS-NMR Data and Machine Learning-Assisted Profiling of Metabolite Fluxes to Classify Low- and High-Grade Gliomas

Tmet-02. Cell-Intrinsic Metabolic Phenotypes Identified In Glioblastoma Patients Using Mass Spectrometry Imaging Of 13C-Labeled Glucose Metabolism

Amino acid metabolism in glioma: in vivo MR-spectroscopic detection of alanine as a potential biomarker of poor survival in glioma patients

Biomarker Identification in Liver Cancers Using Desorption Electrospray Ionization Mass Spectrometry (DESI-MS) Imaging: An Approach for Spatially Resolved Metabolomics

Optimized Mass Spectrometry Analysis Workflow with Polarimetric Guidance for ex vivo and in situ Sampling of Biological Tissues

Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging

Metabolic Approach for Tumor Delineation in Glioma Surgery: 3d Mr Spectroscopy Image-Guided Resection

Establishment of Diagnostic Model of Cerebrospinal Protein Fingerprint Pattern for Glioma and Its Clinical Application

Quantitative diffusion weighted magnetic resonance spectroscopy of glioma and metastatic tumor in human brain in vivo

Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes and detects early response to chemoradiotherapy